Loading...

Avacta Group

AIM:AVCT
Snowflake Description

Flawless balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
AVCT
AIM
£33M
Market Cap
  1. Home
  2. GB
  3. Pharmaceuticals & Biotech
Company description

Avacta Group Plc offers reagents and therapeutics based on Affimer technology for diagnostic and research applications in the United Kingdom. The last earnings update was 78 days ago. More info.


Add to Portfolio Compare Print
  • Avacta Group has significant price volatility in the past 3 months.
AVCT Share Price and Events
7 Day Returns
-1.7%
AIM:AVCT
-0.1%
GB Biotechs
0.4%
GB Market
1 Year Returns
1.7%
AIM:AVCT
24.2%
GB Biotechs
-1.9%
GB Market
AVCT Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Avacta Group (AVCT) -1.7% 3.5% -18.5% 1.7% -67.6% -73.7%
GB Biotechs -0.1% 2.7% 5% 24.2% 13.6% 53.2%
GB Market 0.4% 1.3% 2.8% -1.9% 23.1% 4.7%
1 Year Return vs Industry and Market
  • AVCT underperformed the Biotechs industry which returned 24.2% over the past year.
  • AVCT outperformed the Market in United Kingdom of Great Britain and Northern Ireland which returned -1.9% over the past year.
Price Volatility
AVCT
Industry
5yr Volatility vs Market

Value

 Is Avacta Group undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Avacta Group. This is due to cash flow or dividend data being unavailable. The share price is £0.295.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Avacta Group's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Avacta Group's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
AIM:AVCT PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-01-31) in GBP £-0.12
AIM:AVCT Share Price ** AIM (2019-06-25) in GBP £0.3
United Kingdom of Great Britain and Northern Ireland Biotechs Industry PE Ratio Median Figure of 5 Publicly-Listed Biotechs Companies 34.48x
United Kingdom of Great Britain and Northern Ireland Market PE Ratio Median Figure of 787 Publicly-Listed Companies 16.36x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Avacta Group.

AIM:AVCT PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= AIM:AVCT Share Price ÷ EPS (both in GBP)

= 0.3 ÷ -0.12

-2.55x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Avacta Group is loss making, we can't compare its value to the GB Biotechs industry average.
  • Avacta Group is loss making, we can't compare the value of its earnings to the United Kingdom of Great Britain and Northern Ireland market.
Price based on expected Growth
Does Avacta Group's expected growth come at a high price?
Raw Data
AIM:AVCT PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.55x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
10%per year
United Kingdom of Great Britain and Northern Ireland Biotechs Industry PEG Ratio Median Figure of 5 Publicly-Listed Biotechs Companies 1.83x
United Kingdom of Great Britain and Northern Ireland Market PEG Ratio Median Figure of 573 Publicly-Listed Companies 1.47x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Avacta Group, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Avacta Group's assets?
Raw Data
AIM:AVCT PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-01-31) in GBP £0.25
AIM:AVCT Share Price * AIM (2019-06-25) in GBP £0.3
United Kingdom of Great Britain and Northern Ireland Biotechs Industry PB Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 2.21x
United Kingdom of Great Britain and Northern Ireland Market PB Ratio Median Figure of 1,371 Publicly-Listed Companies 1.49x
AIM:AVCT PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= AIM:AVCT Share Price ÷ Book Value per Share (both in GBP)

= 0.3 ÷ 0.25

1.17x

* Primary Listing of Avacta Group.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Avacta Group is good value based on assets compared to the GB Biotechs industry average.
X
Value checks
We assess Avacta Group's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Avacta Group has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Avacta Group expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
10%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Avacta Group expected to grow at an attractive rate?
  • Unable to compare Avacta Group's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Avacta Group's earnings growth to the United Kingdom of Great Britain and Northern Ireland market average as it is expected to be loss making during the next 1-3 years.
  • Avacta Group's revenue growth is expected to exceed the United Kingdom of Great Britain and Northern Ireland market average.
Annual Growth Rates Comparison
Raw Data
AIM:AVCT Future Growth Rates Data Sources
Data Point Source Value (per year)
AIM:AVCT Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 10%
AIM:AVCT Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 32.1%
United Kingdom of Great Britain and Northern Ireland Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 12.3%
United Kingdom of Great Britain and Northern Ireland Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 4%
United Kingdom of Great Britain and Northern Ireland Market Earnings Growth Rate Market Cap Weighted Average 10.4%
United Kingdom of Great Britain and Northern Ireland Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
AIM:AVCT Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in GBP Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
AIM:AVCT Future Estimates Data
Date (Data in GBP Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 6 1
2021-07-31 6 -4 -7 2
2020-12-31 5 -10 2
2020-07-31 4 -6 -9 2
2019-12-31 4 -10 2
2019-07-31 3 -6 -11 2
AIM:AVCT Past Financials Data
Date (Data in GBP Millions) Revenue Cash Flow Net Income *
2019-01-31 2 -5 -10
2018-10-31 3 -5 -9
2018-07-31 3 -5 -9
2018-04-30 3 -6 -8
2018-01-31 3 -6 -7
2017-10-31 3 -5 -7
2017-07-31 3 -4 -6
2017-04-30 3 -4 -6
2017-01-31 2 -5 -6
2016-10-31 2 -4 -5
2016-07-31 2 -4 -5
2016-04-30 2 -3 -5

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Avacta Group is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Avacta Group's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
AIM:AVCT Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Avacta Group Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

AIM:AVCT Future Estimates Data
Date (Data in GBP Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31
2021-07-31 -0.06 -0.06 -0.07 2.00
2020-12-31 -0.09 -0.09 -0.09 1.00
2020-07-31 -0.08 -0.07 -0.08 2.00
2019-12-31 -0.09 -0.09 -0.09 1.00
2019-07-31 -0.09 -0.08 -0.10 2.00
AIM:AVCT Past Financials Data
Date (Data in GBP Millions) EPS *
2019-01-31 -0.12
2018-10-31 -0.12
2018-07-31 -0.13
2018-04-30 -0.12
2018-01-31 -0.11
2017-10-31 -0.10
2017-07-31 -0.10
2017-04-30 -0.10
2017-01-31 -0.09
2016-10-31 -0.08
2016-07-31 -0.07
2016-04-30 -0.08

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Avacta Group will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Avacta Group's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Avacta Group has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Avacta Group performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Avacta Group's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Avacta Group does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Avacta Group's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Avacta Group's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Avacta Group's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Avacta Group Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

AIM:AVCT Past Revenue, Cash Flow and Net Income Data
Date (Data in GBP Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-01-31 2.27 -10.08 7.82 4.72
2018-10-31 2.52 -9.45 7.76 4.25
2018-07-31 2.76 -8.83 7.70 3.78
2018-04-30 2.85 -7.86 7.69 3.29
2018-01-31 2.94 -6.89 7.69 2.80
2017-10-31 2.84 -6.63 7.43 2.70
2017-07-31 2.74 -6.37 7.18 2.60
2017-04-30 2.56 -6.34 6.95 2.46
2017-01-31 2.38 -6.32 6.72 2.33
2016-10-31 2.27 -5.48 6.08 1.92
2016-07-31 2.17 -4.65 5.43 1.50
2016-04-30 2.15 -4.86 4.99 0.99
2016-01-31 2.14 -5.06 4.55 0.48
2015-10-31 1.97 -4.98 4.48 0.26
2015-07-31 1.81 -4.89 4.41 0.03
2015-04-30 1.67 -3.83 4.13 0.02
2015-01-31 1.53 -2.76 3.85
2014-10-31 1.57 -2.12 3.38
2014-07-31 1.62 -1.47 2.90
2014-04-30 1.99 -1.24 2.90
2014-01-31 2.37 -1.01 2.90
2013-10-31 2.53 -1.26 3.14
2013-07-31 2.70 -1.52 3.39
2013-04-30 2.63 -1.54 3.34
2013-01-31 2.56 -1.56 3.29
2012-10-31 2.85 -1.34 3.22
2012-07-31 3.13 -1.11 3.15

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Avacta Group has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Avacta Group has efficiently used its assets last year compared to the GB Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Avacta Group improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Avacta Group's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Avacta Group has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Avacta Group's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Avacta Group's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Avacta Group is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Avacta Group has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Avacta Group's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Avacta Group has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Avacta Group Company Filings, last reported 4 months ago.

AIM:AVCT Past Debt and Equity Data
Date (Data in GBP Millions) Total Equity Total Debt Cash & Short Term Investments
2019-01-31 27.33 0.00 11.79
2018-10-31 27.33 0.00 11.79
2018-07-31 21.41 0.00 5.22
2018-04-30 21.41 0.00 5.22
2018-01-31 26.18 0.00 8.28
2017-10-31 26.18 0.00 8.28
2017-07-31 29.89 0.00 13.17
2017-04-30 29.89 0.00 13.17
2017-01-31 32.62 0.00 16.13
2016-10-31 32.62 0.00 16.13
2016-07-31 35.86 0.00 19.52
2016-04-30 35.86 0.00 19.52
2016-01-31 38.52 0.00 24.98
2015-10-31 38.52 0.00 24.98
2015-07-31 19.13 0.00 7.33
2015-04-30 19.13 0.00 7.33
2015-01-31 22.35 0.00 7.86
2014-10-31 22.35 0.00 7.86
2014-07-31 28.84 0.00 11.48
2014-04-30 28.84 0.00 11.48
2014-01-31 19.68 0.00 3.25
2013-10-31 19.68 0.00 3.25
2013-07-31 15.55 0.00 0.58
2013-04-30 15.55 0.00 0.58
2013-01-31 16.20 0.00 2.06
2012-10-31 16.20 0.00 2.06
2012-07-31 16.96 0.00 4.19
  • Avacta Group has no debt.
  • Avacta Group has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Avacta Group has sufficient cash runway for 1.6 years based on current free cash flow.
  • Avacta Group has sufficient cash runway for 1.6 years if free cash flow continues to grow at historical rates of -0% each year.
X
Financial health checks
We assess Avacta Group's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Avacta Group has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Avacta Group's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Avacta Group dividends.
If you bought £2,000 of Avacta Group shares you are expected to receive £0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Avacta Group's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Avacta Group's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
AIM:AVCT Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.8%
United Kingdom of Great Britain and Northern Ireland Market Average Dividend Yield Market Cap Weighted Average of 706 Stocks 4.3%
United Kingdom of Great Britain and Northern Ireland Minimum Threshold Dividend Yield 10th Percentile 1%
United Kingdom of Great Britain and Northern Ireland Bottom 25% Dividend Yield 25th Percentile 2%
United Kingdom of Great Britain and Northern Ireland Top 25% Dividend Yield 75th Percentile 5.4%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

AIM:AVCT Future Dividends Estimate Data
Date (Data in £) Dividend per Share (annual) Avg. No. Analysts
2021-12-31
2021-07-31
2020-12-31
2020-07-31
2019-12-31
2019-07-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Avacta Group has not reported any payouts.
  • Unable to verify if Avacta Group's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Avacta Group's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Avacta Group has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Avacta Group's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Avacta Group afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Avacta Group has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Avacta Group's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Alastair Smith
COMPENSATION £208,000
TENURE AS CEO 14.4 years
CEO Bio

Prof. Alastair Smith Co-founded Avacta Group Plc in January 2004 and has been its Chief Executive Officer since 2005. Prof. Smith serves as the Chief Executive Officer of Avacta Ltd. He is a Professor of Molecular Biophysics, Head of the Molecular and Nanoscale Physics Group in the School of Physics and Astronomy and Director of the Interdisciplinary Institute of Molecular Biophysics. His early research focused on nonlinear optics and exciton dynamics in polymeric materials and liquid crystals. He took up a position at the University of Leeds as a Leverhulme Special Research Fellow in 1995. He became the founder and first Director of the Institute of Molecular Biophysics at Leeds University. He has served as chairman of Molecular Biophysics at Leeds University. Prof. Smith serves as a Director of Curidium Medica Limited. He serves as an Executive Director of Avacta Group Plc. He is a biophysicist of world renown. He has published over 70 articles since 1997. He holds a post-doctoral in the USA with renowned spectroscopist Professor Robin Hochstrasser at the University of Pennsylvania. Prof. Smith has a degree and PhD in Physics from Manchester University.

CEO Compensation
  • Alastair's compensation has increased whilst company is loss making.
  • Alastair's remuneration is about average for companies of similar size in United Kingdom of Great Britain and Northern Ireland.
Management Team Tenure

Average tenure of the Avacta Group management team in years:

3.4
Average Tenure
  • The tenure for the Avacta Group management team is about average.
Management Team

Alastair Smith

TITLE
CEO & Executive Director
COMPENSATION
£208K
TENURE
14.4 yrs

Tony Gardiner

TITLE
CFO, Company Secretary & Executive Director
COMPENSATION
£161K
AGE
47
TENURE
3.4 yrs

Michael Albin

TITLE
COMPENSATION
£20K
TENURE
1.3 yrs

Matt Johnson

TITLE
Chief Technology Officer
TENURE
3.4 yrs

Amrik Basran

TITLE
Chief Scientific Officer
TENURE
6.4 yrs

Craig Slater

TITLE
Chief Operating Officer of Avacta Animal Health
COMPENSATION
£69K
AGE
55
TENURE
2.8 yrs

Philippe Cotrel

TITLE
Chief Commercial Officer
TENURE
3.4 yrs

Jose Saro

TITLE
Chief Medical Officer
TENURE
0.5 yrs
Board of Directors Tenure

Average tenure and age of the Avacta Group board of directors in years:

3.3
Average Tenure
56
Average Age
  • The tenure for the Avacta Group board of directors is about average.
Board of Directors

Eliot Forster

TITLE
Non-Executive Chairman
COMPENSATION
£12K
AGE
51
TENURE
1 yrs

Alastair Smith

TITLE
CEO & Executive Director
COMPENSATION
£208K

Tony Gardiner

TITLE
CFO, Company Secretary & Executive Director
COMPENSATION
£161K
AGE
47
TENURE
3.4 yrs

AJ Aubrey

TITLE
Non-Executive Director
COMPENSATION
£25K
AGE
56

Trevor Nicholls

TITLE
Non-Executive Director
COMPENSATION
£35K
AGE
61
TENURE
5.8 yrs

Mike Owen

TITLE
Chairman of Scientific Advisory Board & Senior Independent Director
COMPENSATION
£30K
AGE
67
TENURE
3.3 yrs

Terry Rabbitts

TITLE
Member of Scientific Advisory Board
TENURE
3.3 yrs

Paul Moss

TITLE
Member of Scientific Advisory Board
TENURE
3.3 yrs

Adrian Hayday

TITLE
Member of Scientific Advisory Board
TENURE
3.3 yrs

Gerard Evan

TITLE
Member of Scientific Advisory Board
TENURE
2.6 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (£) Value (£)
02. Jan 19 Buy Tony Gardiner Individual 31. Dec 18 31. Dec 18 8,196 £0.31 £2,500
X
Management checks
We assess Avacta Group's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Avacta Group has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Imagine Owning Avacta Group (LON:AVCT) And Trying To Stomach The 74% Share Price Drop

For example, we sympathize with anyone who was caught holding Avacta Group Plc (LON:AVCT) during the five years that saw its share price drop a whopping 74%. … Some Avacta Group investors have already had a taste of the bitterness stocks like this can leave in the mouth. … With the share price down 24% per year, over 5 years, it seems likely that the need for cash is weighing on investors' minds.

Simply Wall St -

Will Avacta Group Plc's (LON:AVCT) Earnings Grow In The Next Couple Of Years?

In July 2018, Avacta Group Plc (LON:AVCT) announced its most recent earnings update, which … that losses became smaller relative to the prior year's level … as a result of recent tailwinds

Simply Wall St -

What does Avacta Group Plc's (LON:AVCT) Balance Sheet Tell Us About Its Future?

However, the trade-off is AVCT will have to follow strict debt obligations which will reduce its financial flexibility. … Is AVCT right in choosing financial flexibility over lower cost of capital … Debt capital generally has lower cost of capital compared to equity funding.

Simply Wall St -

Does Avacta Group Plc's (LON:AVCT) CEO Salary Reflect Performance?

How Does Alastair Smith's Compensation Compare With Similar Sized Companies. … At the time of writing our data says that Avacta Group Plc has a market cap of UK£20m, and is paying total annual CEO compensation of UK£208k. … We took a group of companies with market capitalizations below UK£158m, and calculated the median CEO compensation to be UK£246k.

Simply Wall St -

What Should We Expect From Avacta Group Plc's (LON:AVCT) Earnings In The Next Couple Of Years?

In July 2018, Avacta Group Plc (LON:AVCT) released its latest earnings announcement, which … that losses became smaller relative to the prrior year's level

Simply Wall St -

Healthcare Stocks: Is Now The Time To Buy Avacta Group Plc (LON:AVCT)?

operates in the healthcare industry, … The demand for new drug development to meet new or persistent chronic illnesses, as well as the ongoing need for biotech drugs as Baby Boomers continue to age, are growth drivers for the optimistic outlook for the biotech industry in the long run … Healthcare analysts are forecasting for the entire industry,

Simply Wall St -

Want To Invest In Avacta Group Plc (LON:AVCT)? Here's How It Performed Lately

Assessing Avacta Group Plc's (AIM:AVCT) past track record of performance is an insightful exercise for investors. … View our latest analysis for Avacta Group Did AVCT perform worse than its track record and industry? … You should continue to research Avacta Group to get a better picture of the stock by looking at: Future Outlook: What are well-informed industry analysts predicting for AVCT’s future growth?

Simply Wall St -

Was Avacta Group Plc's (LON:AVCT) Earnings Decline A Part Of Broader Industry Downturn?

See our latest analysis for Avacta Group Was AVCT's recent earnings decline indicative of a tough track record? … I like to use data from the most recent 12 months, which either annualizes the most recent 6-month earnings update, or in some cases, the most recent annual report is already the latest available financial data. … For Avacta Group, its latest earnings (trailing twelve month) is -£6.4M, which, relative to the previous year's figure, has become more negative.

Simply Wall St -

Will Avacta Group Plc's (LON:AVCT) Earnings Grow Over The Couple Of Years?

The most recent earnings update Avacta Group Plc's (AIM:AVCT) released in July 2017 showed that losses became smaller relative to the prrior year's level as a result of recent tailwinds Today I want to provide a brief commentary on how market analysts view Avacta Group's earnings growth trajectory over the next couple of years and whether the future looks brighter. … Check out our latest analysis for Avacta Group Market analysts' consensus outlook for the coming year seems pessimistic, with earnings becoming even more negative, reaching £-8.5M in 2019. … The advantage of this approach is that it ignores near term flucuations and accounts for the overarching direction of Avacta Group's earnings trajectory over time, fluctuate up and down.

Simply Wall St -

What Does Avacta Group Plc's (LON:AVCT) Share Price Indicate?

Let’s take a look at Avacta Group’s outlook and value based on the most recent financial data to see if there are any catalysts for a price change. … The stock’s ratio of 1.42x is currently trading slightly below its industry peers’ ratio of 2.44x, which means if you buy Avacta Group today, you’d be paying a relatively fair price for it. … Furthermore, it seems like Avacta Group’s share price is quite stable, which means there may be less chances to buy low in the future now that it’s fairly valued.

Simply Wall St -

Company Info

Description

Avacta Group Plc offers reagents and therapeutics based on Affimer technology for diagnostic and research applications in the United Kingdom. It operates in two segments, Life Sciences and Animal Health. The company’s custom Affimer products are also used in drugs and biomarkers discovery in biotech research and development activities. In addition, it provides tools and contract services to assist the diagnosis of conditions in animals to enable treatment for veterinarians. The company has a research partnership with Moderna Therapeutics; research collaboration with OncoSec Medical Incorporated for gene delivery of therapeutic Affimers; co-development partnership agreement with Bach Biosciences LLP to develop Affimer drug conjugate therapies; research collaboration with FIT Biotech Oy; drug development collaboration with Iksuda Therapeutics; and a partnership with Selexis to develop cell line for clinical manufacturing, as well as with Tufts University School of Medicine for developing Affimer drug conjugate therapies. Avacta Group Plc was incorporated in 2003 and is based in Wetherby, the United Kingdom.

Details
Name: Avacta Group Plc
AVCT
Exchange: AIM
Founded: 2003
£33,313,116
112,925,817
Website: http://www.avacta.com
Address: Avacta Group Plc
Thorp Arch Estate,
Unit 20,
Wetherby,
West Yorkshire, LS23 7FA,
United Kingdom
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
AIM AVCT Ordinary Shares London Stock Exchange AIM Market GB GBP 11. Aug 2006
Number of employees
Current staff
Staff numbers
114
Avacta Group employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/06/26 02:36
End of day share price update: 2019/06/25 00:00
Last estimates confirmation: 2019/06/20
Last earnings filing: 2019/04/09
Last earnings reported: 2019/01/31
Last annual earnings reported: 2018/07/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.